Chronic Kidney Disease, Gut Dysbiosis, and Constipation: A Burdensome Triplet
- PMID: 33255763
- PMCID: PMC7760012
- DOI: 10.3390/microorganisms8121862
Chronic Kidney Disease, Gut Dysbiosis, and Constipation: A Burdensome Triplet
Abstract
Gut dysbiosis has been implicated in the progression of chronic kidney disease (CKD). Alterations in the gut environment induced by uremic toxins, the dietary restriction of fiber-rich foods, and multiple drugs may be involved in CKD-related gut dysbiosis. CKD-related gut dysbiosis is considered to be characterized by the expansion of bacterial species producing precursors of harmful uremic toxins, such as indoxyl sulfate and p-cresyl sulfate, and the contraction of species generating beneficial short-chain fatty acids, such as butyrate. Gut-derived uremic toxins cause oxidative stress and pro-inflammatory responses, whereas butyrate exerts anti-inflammatory effects and contributes to gut epithelial integrity. Gut dysbiosis is associated with the disruption of the gut epithelial barrier, which leads to the translocation of endotoxins. Research on CKD-related gut dysbiosis has mainly focused on chronic inflammation and consequent cardiovascular and renal damage. The pathogenic relationship between CKD-related gut dysbiosis and constipation has not yet been investigated in detail. Constipation is highly prevalent in CKD and affects the quality of life of these patients. Under the pathophysiological state of gut dysbiosis, altered bacterial fermentation products may play a prominent role in intestinal dysmotility. In this review, we outline the factors contributing to constipation, such as the gut microbiota and bacterial fermentation; introduce recent findings on the pathogenic link between CKD-related gut dysbiosis and constipation; and discuss potential interventions. This pathogenic link needs to be elucidated in more detail and may contribute to the development of novel treatment options not only for constipation, but also cardiovascular disease in CKD.
Keywords: butyrate; chronic kidney disease; constipation; dysbiosis; gut epithelial integrity; gut microbiota; gut-derived uremic toxins; inflammation; intestinal motility; short-chain fatty acids.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The Impact of CKD on Uremic Toxins and Gut Microbiota.Toxins (Basel). 2021 Mar 31;13(4):252. doi: 10.3390/toxins13040252. Toxins (Basel). 2021. PMID: 33807343 Free PMC article. Review.
-
Dietary strategies for gut-derived protein-bound uremic toxins and cardio-metabolic risk factors in chronic kidney disease: A focus on dietary fibers.Crit Rev Food Sci Nutr. 2023;63(19):3994-4008. doi: 10.1080/10408398.2021.1996331. Epub 2021 Oct 27. Crit Rev Food Sci Nutr. 2023. PMID: 34704501 Review.
-
Altered microbiome in chronic kidney disease: systemic effects of gut-derived uremic toxins.Clin Sci (Lond). 2018 Mar 9;132(5):509-522. doi: 10.1042/CS20171107. Print 2018 Mar 15. Clin Sci (Lond). 2018. PMID: 29523750 Review.
-
Link between gut microbiota dysbiosis and chronic kidney disease.Eur Rev Med Pharmacol Sci. 2022 Mar;26(6):2057-2074. doi: 10.26355/eurrev_202203_28354. Eur Rev Med Pharmacol Sci. 2022. PMID: 35363356
-
The interplay among gut microbiota, hypertension and kidney diseases: The role of short-chain fatty acids.Pharmacol Res. 2019 Mar;141:366-377. doi: 10.1016/j.phrs.2019.01.019. Epub 2019 Jan 10. Pharmacol Res. 2019. PMID: 30639376 Review.
Cited by
-
Gut microbiota-derived SCFAs and MetS-related nephropathy.Front Nutr. 2025 Jul 8;12:1561271. doi: 10.3389/fnut.2025.1561271. eCollection 2025. Front Nutr. 2025. PMID: 40697558 Free PMC article. Review.
-
Gut microbiota-targeted therapies in pediatric chronic kidney disease: gaps and opportunities.Pediatr Nephrol. 2025 May 1. doi: 10.1007/s00467-025-06789-z. Online ahead of print. Pediatr Nephrol. 2025. PMID: 40307477 Review.
-
Emerging trends and focus for the link between the gastrointestinal microbiome and kidney disease.Front Cell Infect Microbiol. 2022 Aug 15;12:946138. doi: 10.3389/fcimb.2022.946138. eCollection 2022. Front Cell Infect Microbiol. 2022. PMID: 36046740 Free PMC article.
-
Life's Simple 7 and its impact on chronic bowel disorders: a study on constipation and diarrhea in the U.S. adult population.Front Med (Lausanne). 2025 Feb 12;12:1516210. doi: 10.3389/fmed.2025.1516210. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40012973 Free PMC article.
-
Probiotics ameliorate IgA nephropathy by improving gut dysbiosis and blunting NLRP3 signaling.J Transl Med. 2022 Aug 29;20(1):382. doi: 10.1186/s12967-022-03585-3. J Transl Med. 2022. PMID: 36038927 Free PMC article.
References
-
- Cano A.E., Neil A.K., Kang J.Y., Barnabas A., Eastwood J.B., Nelson S.R., Hartley I., Maxwell D. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am. J. Gastroenterol. 2007;102:1990–1997. doi: 10.1111/j.1572-0241.2007.01321.x. - DOI - PubMed
-
- Ikee R., Yano K., Tsuru T. Constipation in chronic kidney disease: It is time to reconsider. Ren. Replace. Ther. 2019;5:51. doi: 10.1186/s41100-019-0246-3. - DOI
-
- Herzog C.A., Asinger R.W., Berger A.K., Charytan D.M., Diez J., Hart R.G., Eckardt K.U., Kasiske B.L., McCullough P.A., Passman R.S., et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int. 2011;80:572–586. doi: 10.1038/ki.2011.223. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources